NCT03732768 - Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 8, 2020

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions

Peritoneal CarcinomatosisOvarian Cancer

Interventions

DRUG

Radspherin

Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days. The Sponsor will provide Radspherin® in single dose glass vial and the dose for each subject will be prepared at the site.

Trial Locations (4)

3000

UZ Leuven, Leuven

Unknown

The Norwegian Radiumhospital, Oslo

Clínica Universidad de Navarra, Madrid

Clínica Universidad de Navarra, Pamplona